Operator: Good day, and welcome to the First Quarter 2012 Earnings Release Conference Call. This call is being recorded.
At this time, I'd like to turn the call over to Mr. John Elicker, Senior Vice President, Investor Relations and Public Affairs. Please go ahead sir.
John Elicker - SVP, Public Affairs and IR: Thank you, Alicia, and good morning everybody. Thanks for joining the call this morning to discuss our Q4 results and 2013 guidance.
With me this morning are Lamberto Andreotti, our Chief Executive Officer; and Charlie Bancroft, our Chief Financial Officer. Both Lamberto and Charlie will have prepared remarks. And then joining us for Q&A are Elliott Sigal, our Chief Scientific Officer; Beatrice Cazala, Executive Vice President, Commercial Operations; and Giovanni Caforio, President of U.S. Pharmaceuticals. Again, Lamberto and Charlie will have prepared remarks and then Elliott, Beatrice and Giovanni will be here for Q&A.
Before we get started, I'll take care of the legal requirements. During this call we'll make statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any subsequent date. We specifically disclaim any obligation to update forward-looking statements even if our estimates change.
We will also discuss non-GAAP financial measures adjusted to exclude certain specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on our website. Lamberto?
Lamberto Andreotti - CEO: Thank you, John. Good morning, everyone. Well we had a strong close to a very important year in just last quarter we grew our in line and new brands by 16% with especially strong performance by ORENCIA, YERVOY, SPRYCEL, ONGLYZA/KOMBIGLYZE, and Baraclude.
We made some important clinical advances most notably with respect to our immuno-oncology and Hepatitis C, and we had several key regulatory successes with European approval of FORXIGA and especially important for the Company, most people approval of ELIQUIS including in the U.S.
In fact this regulatory accomplishment underscored the importance of 2012 as a year of significant transition for Bristol-Myers Squibb, one that brought our portfolio of the future into sharper perspective and laid the ground work for this year’s focus on our commercial opportunities.
ELIQUIS was the big story of the quarter, by gaining back-to-back approvals in Europe, Canada, Japan, the U.S. and South Korea, this differentiated us that set us up for a strong start to the New Year. Next week along with our partner Pfizer, we will be launching ELIQUIS in the U.S., our teams had been working together, planning for this day, preparing for our launch. We are ready, ready to move forward and while we have already in few markets such as the U.S., Germany and Denmark, we are making similar preparations in the other markets too.